Challenges to the development of new agents for molecularly defined patient subsets: Lessons from BRCA1/2-associated breast cancer

SM Domchek, G Mitchell, GJ Lindeman, NM Tung, J Balmaña, SJ Isakoff, R Schmutzler, MW Audeh, N Loman, C Scott, M Friedlander, B Kaufman, JE Garber, A Tutt, ME Robson